Verrica Pharmaceuticals Inc. is a US-based pharmaceutical company dedicated to developing and commercializing therapeutic solutions for various skin diseases. Its primary investigational compound, VP-102, has successfully completed Phase II clinical trials for molluscum contagiosum and external genital warts, and is presently in Phase II development for common warts. Additionally, the company is advancing VP-103, a cantharidin-based product candidate, designed to treat plantar warts. Verrica maintains a strategic license and collaboration agreement with Torii Pharmaceutical Co., Ltd., focusing on the development and commercialization of its product candidates, including VP-102, for molluscum contagiosum and common warts in the Japanese market. Furthermore, a separate licensing agreement with Lytix Biopharma AS allows for the development and commercialization of LTX-315 for dermatological oncology applications. Verrica Pharmaceuticals Inc. was established in 2013 and has its headquarters in West Chester, Pennsylvania.
